<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02258971</url>
  </required_header>
  <id_info>
    <org_study_id>1205.8</org_study_id>
    <nct_id>NCT02258971</nct_id>
  </id_info>
  <brief_title>Metabolism and Pharmacokinetics of [14C] BEA 2180 BR Administered Orally Compared to [14C] BEA 2180 BR Administered Intravenously in Healthy Male Volunteers</brief_title>
  <official_title>Investigation of the Metabolism and Pharmacokinetics of 1200 μg (Free Cation) [14C] BEA 2180 BR Administered Orally Compared to 500 μg (Free Cation) [14C] BEA 2180 BR Administered Intravenously in Healthy Male Volunteers in an Open Label, Single-dose and Parallel Study Design</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Primary objectives: To determine the basic pharmacokinetics of BEA 2180 BR, its metabolites&#xD;
      CD 1975 ZW and CD 1976 ZW and radioactivity including excretion mass balance, excretion&#xD;
      pathways and metabolism following the oral and intravenous administration of [14C] BEA 2180&#xD;
      BR&#xD;
&#xD;
      Secondary objectives: To determine safety and tolerability following single dose oral and iv&#xD;
      administration of BEA 2180 BR in healthy male volunteers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Individual time course profiles of [14C] radioactivity</measure>
    <time_frame>Up to 312 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Individual time course profiles of BEA 2180 and its metabolites CD 1975 ZW and CD 1976 ZW</measure>
    <time_frame>Up to 312 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate and extent of excretion mass balance based on the total radioactivity in urine and faeces</measure>
    <time_frame>Up to 312 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Elucidation of metabolite structures and identification of major metabolites in plasma, urine, and faeces (if feasible) in comparison with various animal species</measure>
    <time_frame>Up to 312 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cblood cells/Cplasma ratio of [14C] -radioactivity</measure>
    <time_frame>Up to 96 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax (maximum concentration of the analyte(s) in plasma)</measure>
    <time_frame>Up to 96 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>tmax (time from dosing to the maximum concentration of the analyte(s) in plasma)</measure>
    <time_frame>Up to 96 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-tz (area under the concentration-time curve of the analyte(s) in plasma over the time interval from 0 to the time of the last quantifiable data point)</measure>
    <time_frame>Up to 96 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-∞ (area under the concentration-time curve of the analyte(s) in plasma over the time interval from 0 to infinity)</measure>
    <time_frame>Up to 96 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>λz (terminal rate constant in plasma)</measure>
    <time_frame>Up to 96 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2 (terminal half-life of the analyte(s) in plasma)</measure>
    <time_frame>Up to 96 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>MRT (mean residence time of the analyte(s) in the body)</measure>
    <time_frame>Up to 96 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CL (total clearance of the analyte in plasma)</measure>
    <time_frame>Up to 96 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vz (apparent volume of distribution during the terminal phase λz)</measure>
    <time_frame>Up to 96 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Vss (apparent volume of distribution at steady state)</measure>
    <time_frame>Up to 96 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>fe0-tz (amount of analyte excreted in urine within the time interval zero to tz in % of dose)</measure>
    <time_frame>Up to 312 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>fefaeces,0-tz (amount of analyte excreted in faeces within the time interval zero to tz in %) of dose, additionally excretion within each sampling interval will be calculated)</measure>
    <time_frame>Up to 312 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>CLR,0-tz (renal clearance of analyte)</measure>
    <time_frame>Up to 96 hours after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Fa (fraction of drug absorbed after oral administration based on radioactivity data) based on oral and i.v. data</measure>
    <time_frame>Up to 96 hours after drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with abnormal findings in physical examination</measure>
    <time_frame>Up to day 29 after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinically significant changes in vital signs</measure>
    <time_frame>Up to day 29 after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with abnormal findings in 12-lead ECG</measure>
    <time_frame>Up to day 29 after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with abnormal changes in clinical laboratory parameters</measure>
    <time_frame>Up to day 29 after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Up to day 29 after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator global clinical assessment on a 4-point scale</measure>
    <time_frame>Up to day 15 after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator assessed local tolerability on a 6-point scale</measure>
    <time_frame>Up to day 15 after first drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BEA 2180 BR oral</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BEA 2180 BR infusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BEA 2180 BR oral</intervention_name>
    <description>Oral solution</description>
    <arm_group_label>BEA 2180 BR oral</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BEA 2180 BR infusion</intervention_name>
    <description>Solution for infusion to be reconstituted with isotonic saline</description>
    <arm_group_label>BEA 2180 BR infusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy males according to the following criteria:&#xD;
&#xD;
             Based upon a complete medical history, including the physical examination, vital signs&#xD;
             (BP, PR), 12-lead electrocardiogram (ECG), clinical laboratory tests&#xD;
&#xD;
          2. Age ≥35 and Age ≤70 years&#xD;
&#xD;
          3. BMI ≥18.5 and BMI ≤29.9 kg/m2 (Body Mass Index)&#xD;
&#xD;
          4. Subjects must agree to minimize the risk of female partners becoming pregnant from the&#xD;
             dosing day until 3 months after the completion of the study. Acceptable methods of&#xD;
             contraception for male volunteers include a vasectomy no less than 3 months prior to&#xD;
             dosing, barrier contraception or a medically accepted contraceptive method. For female&#xD;
             partners of male volunteers, acceptable methods of contraception include intra-uterine&#xD;
             device, tubal ligation, hormonal contraceptive since at least two months and diaphragm&#xD;
             with spermicide&#xD;
&#xD;
          5. Signed and dated written informed consent prior to admission to the study in&#xD;
             accordance with Good Clinical Practice (GCP) and the local legislation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any finding of the medical examination (including blood pressure (BP), pulse rate (PR)&#xD;
             and ECG) deviating from normal and of clinical relevance&#xD;
&#xD;
          2. Any evidence of a clinically relevant concomitant disease&#xD;
&#xD;
          3. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,&#xD;
             immunological or hormonal disorders&#xD;
&#xD;
          4. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or&#xD;
             neurological disorders&#xD;
&#xD;
          5. History of relevant orthostatic hypotension, fainting spells or blackouts&#xD;
&#xD;
          6. Chronic or relevant acute infections&#xD;
&#xD;
          7. History of relevant allergy/hypersensitivity (including allergy to study drug or its&#xD;
             excipients)&#xD;
&#xD;
          8. Intake of drugs with a long half-life (&gt; 24 hours) within at least one month or less&#xD;
             than 10 half-lives of the respective drug prior to administration or during the trial&#xD;
&#xD;
          9. Use of drugs which might reasonably influence the results of the trial based on the&#xD;
             knowledge at the time of protocol preparation within 10 days prior to administration&#xD;
             or during the trial&#xD;
&#xD;
         10. Participation in another trial with an investigational drug within two months prior to&#xD;
             administration or during the trial&#xD;
&#xD;
         11. Smoker (&gt; 10 cigarettes or &gt; 3 cigars or &gt; 3 pipes/day)&#xD;
&#xD;
         12. Inability to refrain from smoking during the stay in the trial centre&#xD;
&#xD;
         13. Alcohol abuse (more than 2 units of alcoholic beverages per day or more than 14 units&#xD;
             per week (1 unit equals 1 pint [285 mL] of beer or lager, 1 glass [125 mL] of wine, 25&#xD;
             mL shot of 40% spirit)more than 60 g/day).&#xD;
&#xD;
         14. Drug abuse&#xD;
&#xD;
         15. Blood donation (more than 100 mL within 60 days prior to study drug administration or&#xD;
             during the trial)&#xD;
&#xD;
         16. Excessive physical activities (within one week prior to administration or during the&#xD;
             trial until follow-up examination)&#xD;
&#xD;
         17. Any laboratory value outside the reference range that is of clinical relevance&#xD;
&#xD;
         18. Inability to comply with dietary regimen of study centre&#xD;
&#xD;
         19. A marked baseline prolongation of QT/Heart rate-corrected QT interval (QTc) interval&#xD;
             (e.g., repeated demonstration of a QTc interval &gt;450 ms)&#xD;
&#xD;
             Exclusion criteria specific for this study:&#xD;
&#xD;
         20. Veins unsuitable for infusion and blood sampling&#xD;
&#xD;
         21. Pulse rate (PR) interval &gt;220 ms or QRS interval &gt;120 ms&#xD;
&#xD;
         22. Exposure to radiation for diagnostic reasons (except dental X-rays and plain X-rays of&#xD;
             thorax and bony skeleton (excluding spinal column)), during work or during&#xD;
             participation in a medical trial in the previous year&#xD;
&#xD;
         23. Irregular defecation pattern (less than once per 2 days)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>September 2014</verification_date>
  <study_first_submitted>October 1, 2014</study_first_submitted>
  <study_first_submitted_qc>October 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2014</study_first_posted>
  <last_update_submitted>October 1, 2014</last_update_submitted>
  <last_update_submitted_qc>October 1, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02258971
org study id: 1205.8
nct id: NCT02258971
lead sponsor: 
Primary objectives: To determine the basic pharmacokinetics of BEA 2180 BR, its metabolites
      CD 1975 ZW and CD 1976 ZW and radioactivity including excretion mass balance, excretion
      pathways and metabolism following the oral and intravenous administration of [14C] BEA 2180
      BR

      Secondary objectives: To determine safety and tolerability following single dose oral and iv
      administration of BEA 2180 BR in healthy male volunteers.
allocation: Non-Randomized
intervention model: Parallel Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: Individual time course profiles of [14C] radioactivity
time frame: Up to 312 hours after drug administration
measure: Individual time course profiles of BEA 2180 and its metabolites CD 1975 ZW and CD 1976 ZW
time frame: Up to 312 hours after drug administration
measure: Rate and extent of excretion mass balance based on the total radioactivity in urine and faeces
time frame: Up to 312 hours after drug administration
measure: Elucidation of metabolite structures and identification of major metabolites in plasma, urine, and faeces (if feasible) in comparison with various animal species
time frame: Up to 312 hours after drug administration
measure: Cblood cells/Cplasma ratio of [14C] -radioactivity
time frame: Up to 96 hours after drug administration
measure: Cmax (maximum concentration of the analyte(s) in plasma)
time frame: Up to 96 hours after drug administration
measure: tmax (time from dosing to the maximum concentration of the analyte(s) in plasma)
time frame: Up to 96 hours after drug administration
measure: AUC0-tz (area under the concentration-time curve of the analyte(s) in plasma over the time interval from 0 to the time of the last quantifiable data point)
time frame: Up to 96 hours after drug administration
measure: AUC0-∞ (area under the concentration-time curve of the analyte(s) in plasma over the time interval from 0 to infinity)
time frame: Up to 96 hours after drug administration
measure: λz (terminal rate constant in plasma)
time frame: Up to 96 hours after drug administration
measure: t1/2 (terminal half-life of the analyte(s) in plasma)
time frame: Up to 96 hours after drug administration
measure: MRT (mean residence time of the analyte(s) in the body)
time frame: Up to 96 hours after drug administration
measure: CL (total clearance of the analyte in plasma)
time frame: Up to 96 hours after drug administration
measure: Vz (apparent volume of distribution during the terminal phase λz)
time frame: Up to 96 hours after drug administration
measure: Vss (apparent volume of distribution at steady state)
time frame: Up to 96 hours after drug administration
measure: fe0-tz (amount of analyte excreted in urine within the time interval zero to tz in % of dose)
time frame: Up to 312 hours after drug administration
measure: fefaeces,0-tz (amount of analyte excreted in faeces within the time interval zero to tz in %) of dose, additionally excretion within each sampling interval will be calculated)
time frame: Up to 312 hours after drug administration
measure: CLR,0-tz (renal clearance of analyte)
time frame: Up to 96 hours after drug administration
measure: Fa (fraction of drug absorbed after oral administration based on radioactivity data) based on oral and i.v. data
time frame: Up to 96 hours after drug administration
measure: Number of participants with abnormal findings in physical examination
time frame: Up to day 29 after first drug administration
measure: Number of participants with clinically significant changes in vital signs
time frame: Up to day 29 after first drug administration
measure: Number of participants with abnormal findings in 12-lead ECG
time frame: Up to day 29 after first drug administration
measure: Number of participants with abnormal changes in clinical laboratory parameters
time frame: Up to day 29 after first drug administration
measure: Number of participants with adverse events
time frame: Up to day 29 after first drug administration
measure: Investigator global clinical assessment on a 4-point scale
time frame: Up to day 15 after first drug administration
measure: Investigator assessed local tolerability on a 6-point scale
time frame: Up to day 15 after first drug administration
arm group label: BEA 2180 BR oral
arm group type: Experimental
arm group label: BEA 2180 BR infusion
arm group type: Active Comparator
intervention type: Drug
intervention name: BEA 2180 BR oral
description: Oral solution
arm group label: BEA 2180 BR oral
intervention type: Drug
intervention name: BEA 2180 BR infusion
description: Solution for infusion to be reconstituted with isotonic saline
arm group label: BEA 2180 BR infusion
criteria: 
gender: Male
minimum age: 35 Years
maximum age: 70 Years
healthy volunteers: Accepts Healthy Volunteers
url: http://trials.boehringer-ingelheim.com
description: Related Info
responsible party type: Sponsor